Novartis unveils promising Fabhalta data for C3 glomerulopathy indication

Novartis released promising data on Fabhalta (iptacopan), its recently approved drug for paroxysmal nocturnal hemoglobinuria, this time for a new indication — a rare disease called C3 glomerulopathy (C3G).